SCHEMBL1481885

SCHEMBL1481885

Oc1ccc(-c2ccc(C=Cc3nc(-c4ccc(Cl)cc4Cl)c[nH]3)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 1/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
AR P10275 1/20 0.37
PTGS1 P23219 2/20 0.37
PTGS2 P35354 2/20 0.37
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
CRHBP P24387 1/20 0.35
RAB9A P51151 1/20 0.35
CRHR2 Q13324 1/20 0.35
HSP90AA1 P07900 2/20 0.35
HSP90AB1 P08238 2/20 0.35
ALPL P05186 3/20 0.34
MARS1 P56192 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
PTGES O14684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481883 1.00 SMN1; SMN2 (0.49) SMN1; SMN2MEN1MAPTKMT2AAR
SCHEMBL1482813 0.96 MEN1 (0.46) SMN1; SMN2MEN1MAPTKMT2AAR
SCHEMBL1482814 0.96 MEN1 (0.46) SMN1; SMN2MEN1MAPTKMT2AAR
SCHEMBL1481927 0.90 MEN1 (0.45) SMN1; SMN2MEN1MAPTKMT2APTGS1
SCHEMBL1481925 0.90 MEN1 (0.45) SMN1; SMN2MEN1MAPTKMT2APTGS1
SCHEMBL1480766 0.89 PTGES (0.44) SMN1; SMN2MEN1MAPTKMT2AKDM4E
SCHEMBL1480764 0.89 PTGES (0.44) SMN1; SMN2MEN1MAPTKMT2AKDM4E
SCHEMBL1480794 0.89 MAPT (0.40) SMN1; SMN2MEN1MAPTKMT2AKDM4E
SCHEMBL1480791 0.89 MAPT (0.40) SMN1; SMN2MEN1MAPTKMT2AKDM4E
SCHEMBL1481731 0.86 SMN1; SMN2 (0.52) SMN1; SMN2MEN1MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ SMN1; SMN2 4575/4885MEN1 3467/4885MAPT 3558/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ SMN1; SMN2 4575/4885MEN1 3467/4885MAPT 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.